Economy/Home · Economy

HLB Group Takes on the Challenge of Solid Tumor CAR-T... Verismo's 'SynKIR-110' Demonstrates Safety and Anti-Tumor Signals in International Journal

The HLB Group has disclosed initial clinical results for its next-generation CAR-T therapy targeting solid tumors. The explanation is that Verismo Therapeutics' candidate drug 'SynKIR-110' simultaneously demonstrated safety and anti-tumor activity signals from the early stages of Phase 1 clinical tr

Wooil Shim
Staff Reporter
8 min read
HLB Group Takes on the Challenge of Solid Tumor CAR-T... Verismo's 'SynKIR-110' Demonstrates Safety and Anti-Tumor Signals in International Journal
CBC News

The HLB Group has disclosed initial clinical results for its next-generation CAR-T therapy targeting solid tumors. The explanation is that Verismo Therapeutics' candidate drug 'SynKIR-110' simultaneously demonstrated safety and anti-tumor activity signals from the early stages of Phase 1 clinical trials in the solid tumor space, which has a higher development difficulty than blood cancers.

Published in the International Journal 'Cancer Discovery'

According to the HLB Group, the interim Phase 1 results of SynKIR-110, a mesothelin-targeted CAR-T therapy under development by Verismo, were featured in 'Cancer Discovery,' an international journal published by the American Association for Cancer Research (AACR). The paper comparatively analyzed three Phase 1 clinical studies of mesothelin-targeted CAR-T therapies presented at the AACR 2026 Annual Meeting. SynKIR-110 was introduced as a candidate that applies a separated signaling structure based on the 'KIR-CAR platform,' which differentiates it from existing CAR-T therapies.

Why is Solid Tumor CAR-T Difficult?

Developing CAR-T therapies for solid tumors is more challenging than for blood cancers. This is because developers must overcome several obstacles: ▲ target protein expression is not uniform across cancer cells, ▲ the tumor microenvironment suppresses immune cell activity, and ▲ 'T cell exhaustion,' a phenomenon where CAR-T cell function deteriorates during the treatment process, must be overcome.

SynKIR-110 is an autologous CAR-T therapy that targets mesothelin on the surface of cancer cells. While mesothelin is expressed at limited levels in normal tissues, it is a protein that shows relatively high expression in several solid tumors, including ovarian cancer, mesothelioma, pancreatic cancer, lung cancer, and cholangiocarcinoma.

Phase 1 Early Results: Safety

The ongoing Phase 1 trial is a first-in-human dose-escalation study evaluating the safety and initial anti-tumor activity of SynKIR-110 in patients with progressive ovarian cancer, mesothelioma, or cholangiocarcinoma who have not responded to prior standard treatments.

The initial analysis included 9 patients enrolled in the first three dose cohorts. According to the company, no dose-limiting toxicities (DLTs) or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed in this patient group. Cytokine release syndrome (CRS) occurred in 3 out of 9 patients, but all were low-grade (Grade 1-2). However, a Grade 4 toxicity related to lymphodepletion preconditioning conducted prior to SynKIR-110 administration was reported in one patient.

Anti-Tumor Activity Signals

In terms of anti-tumor activity, tumor size reduction was confirmed in 4 out of the total 9 patients. The company explained that among these, one patient's tumor size decreased by up to 47%, and another patient achieved a partial response (PR) that was maintained at the 6-month follow-up mark.

Cautious Interpretation Needed... Follow-up Clinical Trials Draw Attention

As these results are from the early clinical stage, they must be interpreted with caution. Given that the number of patients is limited to 9 and the dose-escalation trial is ongoing, it is necessary to verify whether the safety and therapeutic efficacy are reproducible in a larger patient population in the future. Nevertheless, attention is focused on future clinical progress as initial signals have been presented exploring the potential to overcome persistence and the tumor microenvironment, which are key challenges in developing solid tumor CAR-T therapies.

[This article was written with the assistance of AI. This article is based on materials released by the HLB Group and does not definitively judge the efficacy or safety of any specific therapy. Clinical trial results may change during subsequent research processes.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.